Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05543200 · ClinicalTrials.gov registry record

BPH Global Registry

A clinical trial of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms, sponsored by Société Internationale d'Urologie.

Recruiting
Registry status
7,500
Enrollment target
20
Study locations

NCT05543200 is a study of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms that is actively recruiting participants, run by Société Internationale d'Urologie. The registered enrollment target is 7,500 participants, above the 293-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (2460% higher). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05543200, a study of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms, is actively recruiting participants, sponsored by Société Internationale d'Urologie.

RECRUITING
Registry status
7,500 participants
Enrollment target
20
Study locations

Study Summary

Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographics and outcomes for patients undergoing surgical treatments for BPH.

Conditions Studied

Benign Prostatic Hyperplasia Lower Urinary Tract Symptoms

Study Locations (20)

Other

  • Hospital Dr. Juan Morey La Unión - La Unión
  • Hospital del Trabajador - Santiago
  • The First Affiliated Hospital, Zhejiang University School of Medicine - Hangzhou
  • University of Cyprus - Nicosia
  • Shariati Hospital - Tehran
  • University of Basrah - Basra
  • Azienda Ospedaliero-Universitaria Careggi - Florence
  • Sapienza University of Rome, Division of Urology, Ospedale Sant'Andrea - Rome
  • American University of Beirut - Beirut
  • Universiti Malaya - Kuala Lumpur
  • Kati University Hospital - Kati
  • Centro Medico Nacional Siglo XXI - Mexico City
  • Benue State University Teaching Hospital, Department of Surgery - Makurdi
  • Ahmadu Bello University Teaching Hospital - Zaria
  • Institute of Kidney Diseases Peshawar - Peshawar
  • Lady Reading Hospital - Peshawar
  • Hamad Medical Corporation Qatar - Doha

California

  • Keck Medicine of USC - Los Angeles

Ontario

  • Toronto Western Hospital, University Health Network - Toronto

Quebec

  • McGill University Health Centre - Montreal

Trial Details

FieldValue
Enrollment Target 7,500 participants
Start Date 2023-03-13
Est. Completion 2027-03

Sponsor

Société Internationale d'Urologie

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05543200

The ClinicalTrials.gov registry entry for NCT05543200 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 7,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 293-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (2460% higher). The listed sponsor is Société Internationale d'Urologie, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Benign Prostatic Hyperplasia appearing as the primary indexed condition, and to 0 interventions.

NCT05543200 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Ontario.

Frequently Asked Questions

What is clinical trial NCT05543200 about?

NCT05543200 is a clinical study titled "BPH Global Registry". Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data a...

What is the current status of trial NCT05543200?

This trial is currently recruiting. The enrollment target is 7,500 participants. The study started on 2023-03-13. Estimated completion is 2027-03.

What conditions does trial NCT05543200 study?

This clinical trial studies the following conditions: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms.

Who is sponsoring clinical trial NCT05543200?

This trial is sponsored by Société Internationale d'Urologie, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05543200 being conducted?

This trial has 20 study locations across California, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Benign Prostatic Hyperplasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Benign Prostatic Hyperplasia

All registered trials for this condition

Lower Urinary Tract Symptoms

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.